Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "Capex"

86 News Found

Limited impact of short-term disruptions, growth momentum to continue in FY 23
News | March 03, 2022

Limited impact of short-term disruptions, growth momentum to continue in FY 23

Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities


Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'
News | February 19, 2022

Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'

Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).


Clean Science and Technology to invest Rs. 300 - 500 Cr on expansion
News | February 16, 2022

Clean Science and Technology to invest Rs. 300 - 500 Cr on expansion

The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals


Divi’s Labs Q3 driven by custom synthesis; margins sustainable: ICICI Direct
News | February 14, 2022

Divi’s Labs Q3 driven by custom synthesis; margins sustainable: ICICI Direct

Key takeaways of recent quarter & conference call highlights


AsterDM Healthcare Q3FY22 PAT at Rs 148.34 cr.
News | February 08, 2022

AsterDM Healthcare Q3FY22 PAT at Rs 148.34 cr.

Aster DM Healthcare has reported consolidated financial results for the period ended December 31, 2021


Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct
News | February 07, 2022

Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct

Key takeaways of recent quarter & conference call highlights


ICRA expects hospitals to report robust revenue and margin expansion in FY22
Hospitals | January 17, 2022

ICRA expects hospitals to report robust revenue and margin expansion in FY22

Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022


Outlook for the Indian Pharma Industry remains stable for this year
Opinion | January 13, 2022

Outlook for the Indian Pharma Industry remains stable for this year

The stability is led by healthy demand in the domestic and emerging markets


Domestic and emerging markets will drive pharma growth: ICRA
News | January 04, 2022

Domestic and emerging markets will drive pharma growth: ICRA

Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters


Most national diagnostic players to deliver double-digit revenue growth in FY2022: ICRA
News | December 15, 2021

Most national diagnostic players to deliver double-digit revenue growth in FY2022: ICRA

During H1 FY2022, the revenues and operating profit margin (OPM) for ICRA sample set showed sharp improvement aided by volume uptick in Covid-19 and allied tests and also demand traction for non-Covid tests